Sign Up:

First Name *

* Required

Last Name *

* Required

Job Title *

* Required

Company *

* Required

Country *

* Required

Email *

* Required

Job Function *

* Required

I would like to speak with an expert from the webinar's sponsor about my research needs *

YesNo * Required

I would like to receive e-mail updates about this sponsor's products and services *

YesNo * Required

To view GEN’s privacy statement click here.

* Required

(*) denotes required form field(s)

Our registration process uses cookies, by submitting this registration form you agree to our cookie policy.

Overview

Already Registered? Click Here

Managing Multiple Biomarker Therapeutic Development

Originally Aired: July 16^th, 2019

For the past two decades, the paradigm in the field has been “one biomarker, one drug,” leading to the development of many targeted therapies and companion diagnostics. As molecular profiling of various cancer types expands, we imagine the use of multiple biomarkers for a combination therapy, like a targeted therapy and immunotherapy together, or even for a monotherapy.

In this roundtable our panelists will discuss assessing the validity of biomarkers to inform drug development and potential combination therapies. Key considerations include predictive testing of biomarkers, analytical methods, drug-diagnostic co-development and potential reimbursement considerations. Dr. Kelly Sullivan, Solutions Manager, N-of-One (a QIAGEN Company) will moderate the discussion with Jeffrey Waldron, Executive Director, Precision Medicine Connective, and Dr. Diana Merino, Science Policy Analyst at Friends of Cancer Research.

A live Q&A session will follow the presentations, offering you a chance to pose questions to our expert panelists.